Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement (OSASPI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02740569 |
Recruitment Status :
Completed
First Posted : April 15, 2016
Last Update Posted : September 7, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Scleroderma, Systemic Sleep Apnea, Obstructive Pulmonary Disease | Other: No intervention |
Scleroderma is an autoimmune disease with skin manifestations and may have pulmonary involvement. OSA may also be seen in scleroderma. Less is known regarding the prevalence of obstructive sleep apnea in scleroderma and its association with pulmonary involvement.
The investigators would like to address the prevalence of OSA in patients with Scleroderma, using overnight cardiorespiratory polygraphy. Other comorbidities and pulmonary findings on computer tomography (CT) as well as lung function tests will be evaluated.
The investigators plan to include 60 patients.
Study Type : | Observational |
Actual Enrollment : | 62 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement |
Study Start Date : | April 2016 |
Actual Primary Completion Date : | October 1, 2016 |
Actual Study Completion Date : | October 1, 2016 |

- Other: No intervention
Observational study. Intervention according to the clinical routines (not included in this part)
- Occurrence of OSA defined by apnea-hypopnea index (AHI) of at least 15/h on the overnight sleep study [ Time Frame: 6 months ]All participants will be evaluated within 6 months
- Occurrence of pulmonary involvement based on computer tomography findings [ Time Frame: 6 months ]All patients will be evaluated within 6 months
Biospecimen Retention: Samples Without DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Known scleroderma diagnosis
- Must be able to give informed consent
Exclusion Criteria:
- Serious neurological and/or psychiatric disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02740569
Turkey | |
Marmara University | |
Istanbul, Pendik, Turkey |
Principal Investigator: | Yuksel Peker, MD, Prof | Marmara University Medical School |
Responsible Party: | Marmara University |
ClinicalTrials.gov Identifier: | NCT02740569 |
Other Study ID Numbers: |
09.2016.208 |
First Posted: | April 15, 2016 Key Record Dates |
Last Update Posted: | September 7, 2018 |
Last Verified: | September 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
scleroderma sleep apnea pulmonary disease |
Lung Diseases Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Scleroderma, Systemic Scleroderma, Diffuse Scleroderma, Localized Respiratory Tract Diseases |
Respiration Disorders Signs and Symptoms, Respiratory Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases Connective Tissue Diseases Skin Diseases |